EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Targeting Prostate Cancer, the ‘Tousled Way’

Siddhant Bhoir, Arrigo De Benedetti iD

International Journal of Molecular Sciences · 2023

DOI: 10.3390/ijms241311100 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, 2023. Verfasst von Siddhant Bhoir und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biochemistry and Molecular Biology, LSU Health Shreveport, Shreveport, LA 71103, USA. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Prostatic Neoplasms, Castration-Resistant. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 149 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Louisiana Cancer Research Center, Louisiana CCRI.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Androgen deprivation therapy (ADT) has been the mainstay of prostate cancer (PCa) treatment, with success in developing more effective inhibitors of androgen synthesis and antiandrogens in clinical practice. However, hormone deprivation and AR ablation have caused an increase in ADT-insensitive PCas associated with a poor prognosis. Resistance to ADT arises through various mechanisms, and most castration-resistant PCas still rely on the androgen axis, while others become truly androgen receptor (AR)-independent. Our research identified the human tousled-like kinase 1 (TLK1) as a crucial early mediator of PCa cell adaptation to ADT, promoting androgen-independent growth, inhibiting apoptosis, and facilitating cell motility and metastasis. Although explicit, the growing role of TLK1 biology in PCa has remained underrepresented and elusive. In this review, we aim to highlight the diverse functions of TLK1 in PCa, shed light on the molecular mechanisms underlying the transition from androgen-sensitive (AS) to an androgen-insensitive (AI) disease mediated by TLK1, and explore potential strategies to counteract this process. Targeting TLK1 and its associated signaling could prevent PCa progression to the incurable metastatic castration-resistant PCa (mCRPC) stage and provide a promising approach to treating PCa.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Prostatic NeoplasmsProstatic Neoplasms, Castration-ResistantMaleHumansAndrogensAndrogen AntagonistsReceptors, AndrogenSignal TransductionOrchiectomyProtein Serine-Threonine Kinases

Stichwörter der Autor:innen

ADTARPCaTLK1 signalingand pathway inhibition

Substanzen

AndrogensAndrogen AntagonistsReceptors, AndrogenTLK1 protein, humanProtein Serine-Threonine Kinases

Autor:innen und Institutionen

  • Department of Biochemistry and Molecular Biology, LSU Health Shreveport, Shreveport, LA 71103, USA.

ORCID-Profile: Arrigo De Benedetti

Förderung

  • Louisiana Cancer Research Center
  • Louisiana CCRI

Zitieren

APA

Bhoir, S., & De Benedetti, A. (2023). Targeting Prostate Cancer, the ‘Tousled Way’. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms241311100

Vancouver

Bhoir S, De Benedetti A. Targeting Prostate Cancer, the ‘Tousled Way’. International Journal of Molecular Sciences. 2023. doi:10.3390/ijms241311100

BibTeX
@article{Bhoir2023,
  author = {Bhoir, Siddhant and De Benedetti, Arrigo},
  title = {Targeting Prostate Cancer, the ‘Tousled Way’},
  journal = {International Journal of Molecular Sciences},
  year = {2023},
  doi = {10.3390/ijms241311100}
}
Kostenlos starten →